Amarin Version 3.0 Weighs Its Options on Promising Omega-3 Pipeline
Executive Summary
Feisty Amarin is certainly undergoing a reincarnation.
You may also be interested in...
Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa
Despite a labeling advantage when it comes to LDL, Amarin’s newly approved Vascepa faces a daunting commercial landscape, competing against Glaxo’s entrenched, soon-to-be generic Lovaza and other options for lowering triglycerides.
Pharma’s Latest Challenge: What To Do About New Provider-Payer Business Models
Even though their specifics are not widely known, the concepts of Medicare's accountable care organizations and other payer-provider linkups are spurring change in the pharmaceutical industry's commercial landscape.
Pharma’s Latest Challenge: What To Do About New Provider-Payer Business Models
Even though their specifics are not widely known, the concepts of Medicare's accountable care organizations and other payer-provider linkups are spurring change in the pharmaceutical industry's commercial landscape.